Libevitug Approved in China as First-in-Class Hepatitis D Treatment
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or...